Broad Spectrum,
Robust Pathogen Reduction

Cerus Final Intercept United States 3

The INTERCEPT® Blood System for Platelets, pathogen reduction system, provides robust, broad spectrum reduction, reducing the risks of TTI, including sepsis,1 as well as transfusion-associated graft-versus-host disease (TA-GVHD).1

bacteria table header2
Bacteria
(gram-negative, gram-positive, spirochetes)
Log Reduction1 (cfu/mL)a,b
Platelets in
65% PAS-3/
35% plasma
Platelets in
100% Plasma
Klebsiella pneumoniae  >6.2 >6.2
Escherichia coli ≥6.3 >5.9
Serratia marcescens ≥6.7c >7.1
Pseudomonas aeruginosa ≥6.7 ≥6.7
Salmonella choleriaesuis 6.2 >5.9
Enterobacter cloacae >6.6 >6.8
Yersenia enterocolitica ≥5.9 >6.3
Staphylococcus epidermidis ≥6.4 >6.5
Staphylococcus aureus ≥6.6 ≥6.5
Listeria monocytogenes ≥6.3c >6.6
Corynebacterium minutissimum ≥5.3 >6.4
Streptococcus pyogenes ≥6.8c >6.1
Bacillus cereus (vegetative) ≥5.5 ≥5.6
Bacillus cereus (spore forming) 3.7c d
Bifidobacterium adolescentis ≥6.0 d
Clostridium perfringens (vegetative) ≥6.5 >6.0
Propionibacterium acnes ≥6.5 >6.7
Treponema pallidum (Syphilis) ≥6.4 >6.3
Borrelia burgdorferi (Lyme disease) ≥6.8 >4.1
     
virus table header2
Virus
(enveloped and non-enveloped)
Log Reduction1 (pfu/mL)a
Platelets in
65% PAS-3/
35% plasma
Platelets in
100% Plasma
HIV-1 IIIB, cell-associated ≥5.4 ≥4.7
HIV-1 IIIB, cell-free ≥5.6 d
HIV-1 Z84 (clinical isolate) ≥3.3 d
HIV-2 CLB-20 (clinical isolate) ≥2.4 d
DHBV (model virus for HBV) ≥4.8 ≥4.3
BVDV (model virus for HCV) ≥4.1 >3.5
HTLV-I 4.7 d
HTLV-II ≥5.1 d
West Nile virus (WNV) ≥6.3 >6.3
Chikungunya virus (CHIKV) ≥5.7 >6.5
Dengue virus (DENV) ≥4.3 3.6
Cytomegalovirus (CMV) ≥4.9 d
Pseudorabies Virus (model for CMV) d ≥4.2
Influenza A virus ≥5.9 d
Calcivirus (model non-enveloped virus) 2.1 0.9
Adenovirus ≥4.9 ≥5.3
Bluetongue virus (model non-enveloped virus) 5.2 4.4
     
Protozoan Parasite Log Reduction1 (pfu or cfu/mL)a
Platelets in
65% PAS-3/
35% plasma
Platelets in
100% Plasma
Plasmodium falciparum ≥6.6 >6.5
Babesia microti ≥4.9 >4.5
Trypanosoma cruzi ≥7.8 >8.4
Leishmania mexicana
(metacyclic promastigote stage)
≥5.0 d
     
Leukocyte Log Reduction1
Platelets in
65% PAS-3/
35% plasma
Platelets in
100% Plasma
Human T-Cells 4 4
     

For a full list of pathogens, see Package Insert.

a. Based on input titer and post-treatment titer in 1 mL, data obtained in platelet components in PAS-3 or plasma compnents

b. Study in progress

c. Based on culture of full platelet unit (300mL).

d. Not tested


References

  1. The INTERCEPT Blood System for Platelets- Dual Storage Set Package Insert, July 17, 2018

*Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.